Known reactions
Observed repeatedly enough to describe, ideally with frequency and population context.
Independent public peptide educationEditorial and review policy
Safety is more than a side-effect list
Known risks and missing data belong on the same page
A short warning list can reflect less research, not lower risk. Product identity, formulation, impurities, immune response, interactions, and follow-up all shape what we can responsibly say.
Serious warnings
Events or contraindications that can materially change the benefit-risk decision.
Unknowns
Questions not answered by the size, duration, population, or design of existing evidence.
Quality risks
Identity, strength, sterility, contaminants, aggregation, storage, and labeling can add risk beyond the molecule itself.
Molecule safety snapshots
Semaglutide
FDA-approved products exist
A central unknown
The safety and composition of an unverified or mislabeled online product cannot be inferred from the name semaglutide.
Tirzepatide
FDA-approved products exist
A central unknown
The actual contents and risk profile of an unverified product cannot be established from a seller's label.
Retatrutide
Investigational, not FDA-approved
A central unknown
Long-term cardiovascular, pancreatic, gallbladder, and other safety outcomes remain under study.
BPC-157
Not FDA-approved; clinical research is emerging
A central unknown
Long-term toxicity, interactions, reproductive effects, cancer-related implications, and risks across routes are not adequately characterized.
TB-500
Not FDA-approved
A central unknown
Systemic, long-term, reproductive, cardiovascular, cancer-related, and interaction risks are not adequately defined.
CJC-1295
Not FDA-approved
A central unknown
Long-term endocrine, metabolic, cardiovascular, and tumor-related consequences are not adequately characterized for unapproved use.
MOTS-c
Not FDA-approved
A central unknown
Long-term metabolic, immune, reproductive, cancer-related, and interaction risks are not adequately known.
Elamipretide (SS-31)
FDA accelerated approval for a specific rare-disease use
A central unknown
Benefits and risks for general longevity, exercise performance, fatigue without Barth syndrome, or other marketed wellness uses are not established by this approval.
When public education stops
Personal symptoms and treatment decisions need clinical care
Peptide Harbor cannot assess an emergency, diagnose a symptom, interpret a personal laboratory result, recommend a medicine or product, or tell someone how to use one. Severe, rapidly worsening, or concerning symptoms require prompt medical care. For non-urgent personal decisions, use a licensed clinician who can review the full medical context.